Skip to Content

ImmuPharma’s Cancer Drug Candidate IPP- 204106 Shows Complete Response to Tumours in Multiple Human Cancer Cell Lines

LONDON, May 20, 2008-ImmuPharma PLC (LSE:IMM), ("ImmuPharma" or the "Company"), the specialist drug discovery and development company, announces today pre-clinical data on its new cancer drug, IPP-204106.

Data on ImmuPharma’s anti-cancer nucleolin antagonist (“Nucant”) peptide programme, IPP-204106 have been obtained confirming the ability of the compounds to effectively control and stop the growth of a large panel of human cancer cell lines both "in vitro" and "in vivo". Collectively the studies comprised breast cancer, prostate cancer, melanoma, glioblastoma, leukaemia, colon cancer and pancreatic cancer cell lines.

The schedule of administration was typically 10 injections over 2 weeks at doses in the range of 1 mg/kg body weight. "In vivo" studies showed that the majority of tumours were completely eradicated and survival time increased without additional treatment.

ImmuPharma has filed appropriate patents on the composition of matter relating to the peptides covering a large variety of Nucant structures. Manufacturing processes transferable to large scale production have also been successfully developed.

Due to the considerable progress made, ImmuPharma has initiated the regulatory studies necessary for the development program of IPP-204106, and ImmuPharma is pursuing grant opportunities from the French national research agencies.

In addition to cancer indications, ImmuPharma believes that Nucants could have use in other areas such as psoriasis, wound healing and diabetic retinopathy and these are currently under investigation in research programs conducted by the CNRS teams and ImmuPharma.

Richard Warr, ImmuPharma's Chairman, commented: "We are delighted by the pre-clinical data shown in our proprietary candidate for oncology. Furthermore, this exciting new drug candidate has a tremendous commercial potential if it meets its target profile of preventing tumour growth as well as metastasis while being non-toxic. This has enhanced further the value of our product pipeline."

Buchanan Communications Reg. in Eng. No. 1499986 45 Moorfields London EC2Y9AE Vat No. GB 245 7021 77

Posted: May 2008